

Resource Summary Report

Generated by [RRID](#) on Sep 6, 2026

PE anti-human/mouse Granzyme B Recombinant

RRID:AB_2687031

Type: Antibody

Proper Citation

BioLegend Cat# 372207, RRID:AB_2687031

Antibody Information

URL: http://antibodyregistry.org/AB_2687031

Proper Citation: BioLegend Cat# 372207, RRID:AB_2687031

Target Antigen: Granzyme B

Host Organism: mouse

Clonality: recombinant monoclonal

Comments: Applications: ICFC

Antibody Name: PE anti-human/mouse Granzyme B Recombinant

Description: This recombinant monoclonal targets Granzyme B

Target Organism: Human, Mouse

Clone ID: Clone QA16A02

Antibody ID: AB_2687031

Vendor: BioLegend

Catalog Number: 372207

Alternative Catalog Numbers: 372208

Record Creation Time: 20231110T034045+0000

Record Last Update: 20260831T220639+0000

Ratings and Alerts

No rating or validation information has been found for PE anti-human/mouse Granzyme B Recombinant.

No alerts have been found for PE anti-human/mouse Granzyme B Recombinant.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 46 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Zeng B, et al. (2026) HE4 drives PD-L1 expression in myeloid cells via IFN- γ -JAK-STAT3 signaling to promote tumor immune evasion. *Cell reports. Medicine*, 7(4), 102691.

Hu J, et al. (2026) Fungal metabolite-based immunotherapy overcomes tumor-associated macrophage immunosuppression. *Cell reports. Medicine*, 7(6), 102833.

Roger A, et al. (2026) Sensory neuron production of substance P and TAF4 promotes disease tolerance during viral infection. *Immunity*, 59(3), 682.

Kong L, et al. (2026) Radiation-Enhanced CD24 Membrane Trafficking via GPI Anchoring Mediates Antitumor Immune Evasion. *Cancer research*, 86(6), 1480.

Pan D, et al. (2026) DGAT1 Inhibition Induces Ferroptosis and Enhances Cancer Immunotherapy Efficacy. *Cancer research*, 86(12), 3026.

Yin Y, et al. (2025) Activated T cells degrade extracellular proteins to enhance effector functions. *Cell reports*, 45(1), 116797.

Guo C, et al. (2025) In situ extended immune activation instantly after tumor resection by oncolytic virus controls postoperative tumor recurrence. *Cell reports. Medicine*, 6(10), 102399.

Wu S, et al. (2025) Selective apoptosis of tumor-associated platelets boosts the anti-metastatic potency of PD-1 blockade therapy. *Cell reports. Medicine*, 6(3), 101984.

Wu ZY, et al. (2025) *Alistipes finegoldii* augments the efficacy of immunotherapy against solid tumors. *Cancer cell*, 43(9), 1714.

Li G, et al. (2025) Microenvironmental γ -TrCP negates amino acid transport to trigger CD8⁺ T cell exhaustion in human non-small cell lung cancer. *Cell reports*, 44(1), 115128.

Qiu Y, et al. (2025) Mannose metabolism reshapes T cell differentiation to enhance anti-tumor immunity. *Cancer cell*, 43(1), 103.

Huang Y, et al. (2025) CD9 antibody enhances the anti-leukemia efficacy of ??T cells in adult B cell acute lymphoblastic leukemia. *iScience*, 28(11), 113752.

Huang SW, et al. (2025) Syngeneic natural killer cell therapy activates dendritic and T cells in metastatic lungs and effectively treats low-burden metastases. *eLife*, 13.

Fang Y, et al. (2025) Protocol to generate allorejection-resistant universal CAR-NKT cells and evaluate their efficacy, mechanism of action, safety, and immunogenicity. *STAR protocols*, 6(2), 103810.

Tu X, et al. (2024) S100A9+CD14+ monocytes contribute to anti-PD-1 immunotherapy resistance in advanced hepatocellular carcinoma by attenuating T cell-mediated antitumor function. *Journal of experimental & clinical cancer research : CR*, 43(1), 72.

Lin F, et al. (2024) Multimodal targeting chimeras enable integrated immunotherapy leveraging tumor-immune microenvironment. *Cell*, 187(26), 7470.

Yin S, et al. (2024) Patient-derived tumor-like cell clusters for personalized chemo- and immunotherapies in non-small cell lung cancer. *Cell stem cell*, 31(5), 717.

Wang C, et al. (2024) Circadian tumor infiltration and function of CD8+ T cells dictate immunotherapy efficacy. *Cell*, 187(11), 2690.

Chun D, et al. (2024) Flt3L enhances clonal diversification and selective expansion of intratumoral CD8+ T cells while differentiating into effector-like cells. *Cell reports*, 43(12), 115023.

Shu G, et al. (2024) PABPC1L Induces IDO1 to Promote Tryptophan Metabolism and Immune Suppression in Renal Cell Carcinoma. *Cancer research*, 84(10), 1659.